Class Effect of Erythropoietin Therapy on Hemoglobin A1c in a Patient with Diabetes Mellitus and Chronic Kidney Disease Not Undergoing Hemodialysis
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
In patients with diabetes mellitus, hemoglobin A 1c (A1C) is commonly interpreted as a measure of long‐term glycemic control, reflecting a mean glucose level over the previous 2–3 months. Although some reports suggest that treatment with recombinant erythropoietin may affect A1C values in patients undergoing hemodialysis, we know of no evidence to support this interaction in patients with chronic renal insufficiency who are not undergoing hemodialysis. In addition, we know of no evidence specific to the treatment effect of epoetin alfa and/or darbepoetin alfa on A1C. We describe a 64‐year‐old man with diabetes, chronic kidney disease, and anemia who was treated consecutively with epoetin alfa and darbepoetin alfa and experienced a temporal reduction in A1C level to a nadir of 4.4%. Throughout approximately 3 years of treatment with these erythropoietin analogs, the patient's total daily dose of insulin was reduced in response to his decreasing A1C values, despite elevated blood glucose levels and the absence of patient‐reported hypoglycemic events. Five months after the patient's erythropoietin therapy was discontinued, his A1C value increased to 8.8%, leading us to conclude that management of the insulin dose may have been different without the falsely lowered A1C levels. Use of the Naranjo adverse drug reaction probability scale indicated a probable association between this patient's reduced A1C levels and erythropoietin therapy. This case demonstrates that both epoetin alfa and darbepoetin alfa may artificially lower A1C levels in a patient with diabetes who is not undergoing dialysis, and therefore this finding can be interpreted as a class effect. Clinicians should be aware of factors that affect A1C values, specifically erythrocyte life span. In patients receiving erythropoietin, therapeutic decisions should be based on A1C and glucose levels, as well as patient symptoms suggestive of hypo‐ or hyperglycemia, to avoid therapy changes that could complicate disease management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Translating the A1C assay into estimated average glucose values
Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., & for the A1c-Derived Average Glucose (ADAG) Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0545 · Cited by 1,812
Standards of Medical Care in Diabetes—2007
American Diabetes Association (2007) · Diabetes Care · doi:10.2337/dc07-s004 · Cited by 1,190
Assessing Glycemia in Diabetes Using Self-monitoring Blood Glucose and Hemoglobin A 1c
Saudek, C. D., Derr, R. L., & Kalyani, R. R. (2006) · JAMA · doi:10.1001/jama.295.14.1688 · Cited by 373
Cited by
Influence of proteinuria on glycated albumin values in diabetic patients with chronic kidney disease
Okada, T., Nakao, T., Matsumoto, H., Nagaoka, Y., Tomaru, R., Iwasawa, H., & Wada, T. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4129 · Cited by 81
“However, it is possible that HbA1c values decrease due to ESA treatment or shortened erythrocyte survival in CKD patients as well as in dialysis patients (18, 19).”
BackgroundA1C: Recommendations, Debates, and Questions
Bloomgarden, Z. T. (2009) · Diabetes Care · doi:10.2337/dc09-zb12 · Cited by 66
Williams, M. E., Mittman, N., Ma, L., Brennan, J. I., Mooney, A., Johnson, C. D., Jani, C. M., Maddux, F. W., & Lacson, E. (2015) · Hemodialysis International · doi:10.1111/hdi.12312 · Cited by 30
Metadata
- Authors
- Brown, J. N., Kemp, D. W., & Brice, K. R.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2009-04
- Volume
- 29
- Issue
- 4
- Pages
- 468-472
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2076802878
- Cited by
- 39
- References
- 3
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.